New Targets in Lung Cancer (Excluding EGFR, ALK, ROS1)
Alessandro Russo(Humanitas University), Christian Rolfo(Icahn School of Medicine at Mount Sinai), Ranee Mehra(University of Maryland, Baltimore), Katherine E. Arensmeyer(University of Maryland, Baltimore), Katherine A. Scilla(University of Maryland, Baltimore), Ana Rita Lopes(Hospital de Egas Moniz), Sandra Gimenez Garrigues(University of Maryland, Baltimore), Michael G. McCusker(University of Maryland, Baltimore), Giuseppina Rosaria Rita Ricciardi
Cited by 58
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
|New England Journal of Medicine|2009|2.4k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort
|Journal of Clinical Oncology|2016|859
Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC
|Journal of Thoracic Oncology|2018|670